TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12212053
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and oxygen
Study: 2202461
Drug: Cyclosporine, 1
Normalized name: CycloSPORINE, 100 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine, 1 mg/kg daily from days 1-28 administered intravenously in four patients and orally in five.
Study: 6988169
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cephradine administered twice daily for 1 week
Study: 6988169
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cephradine administered 4-times a day
Study: 30520252
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine (IG)
Study: 18387078
Drug: Neutral Protamine
Normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral Protamine Hagedorn (NPH) insulin
Study: 21362084
Drug: VAC(®) Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC(®) Therapy System
Study: 21316208
Drug: DHA (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (220 mg/day)
Study: 18955102
Drug: DHA+AA (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA+AA (220 mg/day each)
Study: 10050456
Drug: Peroral pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral pulse therapy with methylprednisolone, 1000 mg daily for three days
Study: 10050456
Drug: Intravenous pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulse therapy with methylprednisolone, 1000 mg daily for three days
Study: 10050456
Drug: Peroral pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral pulse therapy with methylprednisolone
Study: 8065284
Drug: Flurbiprofen 100
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 100 mg tablet, twice daily
Study: 8065284
Drug: Flurbiprofen mouthwash
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen mouthwash 10 ml (0.25%), rinsed 6 times daily for three minutes
Study: 3385024
Drug: 2% minoxidil
Normalized name: MINOXIDIL 2 g in 100 mL TOPICAL LIQUID [2% Minoxidil hair growth serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% minoxidil gel
Study: 22993340
Drug: Exemestane therapy
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane therapy for 30 months
Study: 22993340
Drug: Analgesics use
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics use
Study: 17715042
Drug: Azithromycin tablet
Normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin tablet (500 mg) from pharmaceutical company 1
Study: 17715042
Drug: Azithromycin tablet
Normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin tablet (500 mg) from pharmaceutical company 2
Study: 17715042
Drug: Azithromycin tablet
Normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin tablet (500 mg) from pharmaceutical company 3
Study: 10684389
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing
Study: 10485389
Drug: Patch test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch test
Study: 8334031
Drug: Clodronate 400
Normalized name: clodronic acid 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 400 mg daily for 30 days, followed by 60 days of no treatment (Group 2)
Study: 8334031
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol 2 mcg for 5 days and clodronate 400 mg daily for additional 25 days, followed by 60 days of no treatment (Group 3)
Study: 30204734
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group 1)
Study: 26508298
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (400 µg/day)
Study: 31352663
Drug: Nutraceutical compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical compounds (red yeast rice, Berberine, Coenzyme Q10, folic acid and chrome) added to diet for 3 months
Study: 28790226
Drug: Metformin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (3 x 500 mg)
Study: 25999334
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by experienced community therapists
Study: 24261946
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a grass pollen tablet for 4 months
Study: 9143001
Drug: Intranasal CRH
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal CRH (20 micrograms every 10 min)
Study: 9143001
Drug: Intranasal CRH
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal CRH
Study: 7802851
Drug: Alprazolam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (5 mg daily)
Study: 3314832
Drug: Colchicine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (mean dose 6.7 mg)
Study: 23044285
Drug: Aripiprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (10 or 30 mg/day)
Study: 21950194
Drug: Warfarin adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin adjusted to maintain INR between 1.5 and 1.9 (Group A)
Study: 21950194
Drug: Warfarin adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin adjusted to maintain INR between 2 and 3 (Group B)
Study: 9495931
Drug: Absorbable collagen
Normalized name: Absorbable collagen sponge bone graft product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbable collagen membrane in guided tissue regeneration (GTR) therapy
Study: 8454791
Drug: Skin testing
Normalized name: INVESTIGATIONAL DIAGNOSTIC AGENTS,SKIN TESTING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin testing with major and minor determinants of benzylpenicillin and minor determinant mixtures of ampicillin, amoxicillin, or cloxacillin
Study: 8454791
Drug: Skin testing
Normalized name: INVESTIGATIONAL DIAGNOSTIC AGENTS,SKIN TESTING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin testing with semisynthetic penicillin reagents derived from ampicillin, amoxicillin, or cloxacillin
Study: 8454791
Drug: Ampicillin and
Normalized name: Ampicillin and sulbactam only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin and amoxicillin
Study: 3755683
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cimetidine with 1 g sucralfate
Study: 6723769
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cimetidine with water
Study: 20211022
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 on day 1 of a 21-day cycle) plus best supportive care (BSC)
Study: 17923543
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (2.5 mg)
Study: 9797791
Drug: Ritonavir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (200 mg every 8 hours)
Study: 9797791
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg every 12 hours)
Study: 9797791
Drug: Ritonavir and
Normalized name: lopinavir and ritonavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritonavir and clarithromycin in combination
Study: 8044016
Drug: TCM‐WM therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM‐WM therapy (oral administration and external treatment of TCM plus wet-compressing with antibiotics)
Study: 8044016
Drug: WM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WM therapy (Western medicine therapy including pain-killer, antibiotics, debridement and dressing change)
Study: 1090718
Drug: Intraperitoneal cephaloridine
Normalized name: cephaloridine
DrugBank: Cefaloridine (DB09008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal cephaloridine (25 mg/kg every 6 hr for 48 hr)
Study: 1090718
Drug: Systemic injection
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic injection of cephaloridine
Study: 31208499
Drug: Early short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early short-term upgrade therapy (ICS/LABA inhaled every morning for 7-10 days)
Study: 27761000
Drug: T80/A5/H12.5 (telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: T80/A5/H12.5 (telmisartan 80 mg/amlodipine 5 mg plus hydrochlorothiazide 12.5 mg)
Study: 27761000
Drug: T80/A5 (telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: T80/A5 (telmisartan 80 mg/amlodipine 5 mg)
Study: 27005658
Drug: Resveratrol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol supplementation (75 mg twice daily)
Study: 20808251
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 μg/kg bolus)
Study: 20808251
Drug: Remifentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.5 μg/kg bolus)
Study: 17295579
Drug: Multidimensional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional treatment foster care (MTFC)
Study: 10215753
Drug: Alniditan 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alniditan 2 mg
Study: 10215753
Drug: Alniditan 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alniditan 4 mg
Study: 6339289
Drug: Halometasone ointment
Normalized name: halometasone
DrugBank: Halometasone (DB13728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halometasone ointment (0.05%)
Study: 6339289
Drug: Fluocortolone +
Normalized name: fluocortolone
DrugBank: Fluocortolone (DB08971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortolone + fluocortolone caproate ointment (0.25% each)
Study: 31696724
Drug: Fully Covered
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully Covered Self-Expandable Biliary Metal Stents (FCSEBMS) placed for treatment of refractory bleed in 7 patients
Study: 26255546
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (200 mg/d)
Study: 27169685
Drug: Alphacalcidol 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphacalcidol 1 μg daily for 6 months
Study: 27169685
Drug: Cholecalciferol 1 000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 1 000 IU daily for 6 months
Study: 23359516
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg QD with lead-in (LI)
Study: 23359516
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD with lead-in (LI)
Study: 23359516
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD
Study: 23359516
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD in mRVR patients
Study: 23359516
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD in GT-1a patients
Study: 23359516
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg QD/LI
Study: 23359516
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD/LI
Study: 19843000
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (20 mg three times daily, increased to 40 mg and 80 mg tid)
Study: 19843000
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (20 mg, 40 mg, and 80 mg tid)
Study: 12539684
Drug: Millimeter wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Millimeter wave treatment (7.1 mm, 43 GHz, 10 mW/cm2)
Study: 12539684
Drug: Millimeter wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Millimeter wave treatment
Study: 12539684
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (soothing treatment)
Study: 9018645
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin (2 mU/min, increased by 2 mU/min at 30-minute intervals) started immediately after PGE2 placement
Study: 9018645
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin (2 mU/min, increased by 2 mU/min at 30-minute intervals) started six hours after PGE2 placement
Study: 25599319
Drug: Platelet Gel
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet Gel Supernatant (PGS) plus supportive medical treatment
Study: 25599319
Drug: Supportive medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive medical treatment alone
Study: 19342442
Drug: No supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplements (Control group)
Study: 16650363
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg atorvastatin for 8 weeks
Study: 11714895
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 5 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Study: 11714895
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 10 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Study: 11714895
Drug: Placebo 0
Normalized name: Norethindrone;Placebo 0.35 MG; NA Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Study: 11714895
Drug: Faster infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster infusion rates of morphine
Study: 11714895
Drug: Morphine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (both doses)
Study: 9137028
Drug: 6-hour heparin
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-hour heparin flushing interval
Study: 9137028
Drug: 8-hour heparin
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-hour heparin flushing interval
Study: 9137028
Drug: 4-hour heparin
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-hour heparin flushing interval
Study: 8181019
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (ACE-I)
Study: 8181019
Drug: Aldosterone antagonists
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone antagonists or alternative RAAS blockers (renin inhibitors or angiotensin II receptor blocking agents)
Study: 2142116
Drug: Intramuscular etofenamate
Normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular etofenamate
Study: 2142116
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac sodium
Study: 580214
Drug: commercial drug
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: commercial drug mixture (acetylsalicylic acid 200 mg; phenacetin 200 mg; codeine phosphor. 10 mg; caffeine anhydr. 50 mg; phenobarbital 25 mg)
Study: 29380610
Drug: Ultrasound enamel
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound enamel preparation
Study: 31102045
Drug: Conventional diamond
Normalized name: diamond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diamond bur preparation
Study: 21665136
Drug: Psychosocial support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial support therapy (PST) control
Study: 19803365
Drug: Cytoflavine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavine (10 mL per 24 hours, for 5 days)
Study: 19803365
Drug: Standard antituberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antituberculosis therapy (placebo control)
Study: 11315893
Drug: Topical GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical GTN (10 mg)
Study: 21067823
Drug: Topical saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical saline
Study: 11315893
Drug: Topical ISDN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ISDN (10 mg)
Study: 11315893
Drug: Topical GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical GTN
Study: 11315893
Drug: Topical ISDN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ISDN
Study: 3568581
Drug: Beta-blockade (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade (2 X 80 mg oral propranolol)
Study: 27108821
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (2.5g intravenous, 5min before tourniquet release)
Study: 24015935
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (350 mg Mg d(‐1), 4 weeks)
Study: 24015935
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (500 mg maltodextrin d(‐1), 4 weeks)
Study: 23541623
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg of EV71 antigen with 150 μg of adjuvant (Group A05)
Study: 23541623
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg of EV71 antigen with 300 μg of adjuvant (Group B10)
Study: 20881846
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR (50-300 mg/day)
Study: 8668894
Drug: High-dose i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose i.v. methylprednisolone
Study: 8668894
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids (1 mg per kilogram of body weight per day)
Study: 2067345
Drug: Prodigiosan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prodigiosan plus ibuprofen
Study: 6409456
Drug: Cholinergic antagonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic antagonist, pirenzepine
Study: 29985775
Drug: Protein-based supplement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-based supplement containing 1546 mg of omega-3 polyunsaturated fatty acid (551 mg EPA and 551 mg DHA) twice daily (FO)
Study: 29985775
Drug: Protein-based supplement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-based supplement containing 1546 mg of omega-3 polyunsaturated fatty acid (FO)
Study: 19958042
Drug: Ondansetron (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.25 mg twice daily for 6 weeks, then 0.5 mg twice daily for 6 weeks)
Study: 15385341
Drug: Esmolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol plus enoximone (initial bolus of 0.5 mg/kg followed by a continuous infusion of 2.5 microg x kg(‐1) x min(‐1))
Study: 2670395
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at 0.5 microgram/min
Study: 2670395
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at 3 microgram/min
Study: 2670395
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion at 0.5 microgram/min
Study: 2670395
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion at 3 microgram/min
Study: 2670395
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at 6 microgram/min
Study: 2670395
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion at 6 microgram/min
Study: 824068
Drug: Inhaled BRL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled BRL 10833, dosage: 40 mg
Study: 23439063
Drug: PC‐DC injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC‐DC injections
Study: 17869451
Drug: C/F chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: C/F chemotherapy, cisplatin dose >or=200 mg/m(2), Stage I‐II disease, negative pelvic lymph nodes
Study: 15319332
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of [(14)C]tesaglitazar (intravenous)
Study: 15319332
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of nonlabeled tesaglitazar (oral)
Study: 24102348
Drug: Oral liarozole
Normalized name: letrozole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liarozole 75 mg
Study: 24102348
Drug: Oral liarozole
Normalized name: letrozole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liarozole 150 mg
Study: 24102348
Drug: Oral liarozole
Normalized name: letrozole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liarozole (both doses)
Study: 22609619
Drug: Acute dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute dose of levodopa
Study: 18078614
Drug: Combination DMARD
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination DMARD therapy (sulfasalazine, methotrexate, hydroxychloroquine)
Study: 18078614
Drug: Single DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single DMARD therapy